Systemic therapies for salivary gland carcinomas: an overview of published clinical trials.

IF 1.8 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE Medicina Oral Patologia Oral Y Cirugia Bucal Pub Date : 2024-03-01 DOI:10.4317/medoral.26264

L-C Silva, M-E Pérez-de-Oliveira, C-M Pedroso, A-A Leite, A-R Santos-Silva, M-A Lopes, G-D Junior, M-D Martins, V-P Wagner, L-P Kowalski, C-H Squarize, R-M Castilho, P-A Vargas

{"title":"Systemic therapies for salivary gland carcinomas: an overview of published clinical trials.","authors":"L-C Silva, M-E Pérez-de-Oliveira, C-M Pedroso, A-A Leite, A-R Santos-Silva, M-A Lopes, G-D Junior, M-D Martins, V-P Wagner, L-P Kowalski, C-H Squarize, R-M Castilho, P-A Vargas","doi":"10.4317/medoral.26264","DOIUrl":null,"url":null,"abstract":"Background: There is no consensus about effective systemic therapy for salivary gland carcinomas (sgcs). Our aim was summarized the clinical trials assessing the systemic therapies (ST) on sgcs.Material and methods: Electronic searches were carried out through MEDLINE/pubmed, EMBASE, Scopus, Web of Science, and the Cochrane Library databases, and gray literature.Results: Seventeen different drugs were evaluated, and the most frequent histological subtype was adenoid cystic carcinoma (n=195, 45.5%). Stable disease, observed in 11 ST, achieved the highest rate in adenoid cystic carcinoma treated with sunitinib. The highest complete (11.1%) and partial response (30.5%) rates were seen in androgen receptor-positive tumors treated with leuprorelin acetate.Conclusions: Despite all the advances in this field, there is yet no effective evidence-based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.","PeriodicalId":49016,"journal":{"name":"Medicina Oral Patologia Oral Y Cirugia Bucal","volume":" ","pages":"e280-e287"},"PeriodicalIF":1.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Oral Patologia Oral Y Cirugia Bucal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4317/medoral.26264","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is no consensus about effective systemic therapy for salivary gland carcinomas (sgcs). Our aim was summarized the clinical trials assessing the systemic therapies (ST) on sgcs.

Material and methods: Electronic searches were carried out through MEDLINE/pubmed, EMBASE, Scopus, Web of Science, and the Cochrane Library databases, and gray literature.

Results: Seventeen different drugs were evaluated, and the most frequent histological subtype was adenoid cystic carcinoma (n=195, 45.5%). Stable disease, observed in 11 ST, achieved the highest rate in adenoid cystic carcinoma treated with sunitinib. The highest complete (11.1%) and partial response (30.5%) rates were seen in androgen receptor-positive tumors treated with leuprorelin acetate.

Conclusions: Despite all the advances in this field, there is yet no effective evidence-based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

唾液腺癌的系统疗法：已发表临床试验综述。

背景：关于唾液腺癌（sgcs）的有效系统疗法，目前尚未达成共识。我们的目的是总结评估唾液腺癌全身疗法（ST）的临床试验：通过 MEDLINE/pubmed、EMBASE、Scopus、Web of Science 和 Cochrane Library 数据库以及灰色文献进行电子检索：评估了 17 种不同的药物，最常见的组织学亚型是腺样囊性癌（195 例，45.5%）。11例ST患者病情稳定，其中接受舒尼替尼治疗的腺样囊性癌比例最高。接受醋酸亮丙瑞林治疗的雄激素受体阳性肿瘤的完全应答率（11.1%）和部分应答率（30.5%）最高：结论：尽管该领域取得了诸多进展，但目前尚无有效的循证ST治疗方案，所有已确定的临床试验均显示完全和部分应答率较低。此外，迫切需要开展转化研究，以确定分子靶点和有效的 ST。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medicina Oral Patologia Oral Y Cirugia Bucal DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

4.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： 1. Oral Medicine and Pathology: Clinicopathological as well as medical or surgical management aspects of diseases affecting oral mucosa, salivary glands, maxillary bones, as well as orofacial neurological disorders, and systemic conditions with an impact on the oral cavity. 2. Oral Surgery: Surgical management aspects of diseases affecting oral mucosa, salivary glands, maxillary bones, teeth, implants, oral surgical procedures. Surgical management of diseases affecting head and neck areas. 3. Medically compromised patients in Dentistry: Articles discussing medical problems in Odontology will also be included, with a special focus on the clinico-odontological management of medically compromised patients, and considerations regarding high-risk or disabled patients. 4. Implantology 5. Periodontology